BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by Analysts
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) have been assigned a consensus rating of "Moderate Buy" from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $113.67.
據MarketBeat.com報道,BioMarin製藥公司(納斯達克代碼:BMRN-GET Rating)的股票已被目前覆蓋該公司的17家券商的共識評級定為“中等買入”。兩名投資分析師對該股的評級為持有,十名分析師對該公司的評級為買入。在去年發佈了該股報告的經紀商中,12個月目標價的平均水平為113.67美元。
A number of research firms recently weighed in on BMRN. Evercore ISI upped their price target on BioMarin Pharmaceutical to $130.00 in a report on Friday, December 2nd. Credit Suisse Group reduced their target price on BioMarin Pharmaceutical from $111.00 to $110.00 and set an "outperform" rating for the company in a report on Thursday, October 27th. TheStreet raised BioMarin Pharmaceutical from a "c" rating to a "b-" rating in a report on Thursday, October 27th. StockNews.com started coverage on BioMarin Pharmaceutical in a report on Wednesday, October 12th. They set a "buy" rating for the company. Finally, Cantor Fitzgerald upped their price target on BioMarin Pharmaceutical from $110.00 to $115.00 in a research report on Wednesday, October 12th.
一些研究公司最近加入了BMRN的行列。在12月2日星期五的一份報告中,Evercore ISI將他們對BioMarin製藥公司的目標價上調至130.00美元。瑞信集團在10月27日週四的一份報告中將BioMarin Pharmtics的目標價從111.00美元下調至110.00美元,併為該公司設定了“跑贏大盤”的評級.華爾街在10月27日星期四的一份報告中將BioMarin製藥公司的評級從C級上調至B-級。StockNews.com在10月12日星期三的一份報告中開始對BioMarin製藥公司進行報道。他們為該公司設定了“買入”評級。最後,康託·菲茨傑拉德在10月12日星期三的一份研究報告中將他們對BioMarin製藥公司的目標價從110.00美元上調至115.00美元。
Insider Activity
內幕活動
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 1,000 shares of the firm's stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $106.89, for a total value of $106,890.00. Following the sale, the chief executive officer now directly owns 320,424 shares in the company, valued at $34,250,121.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 1,000 shares of the firm's stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $106.89, for a total value of $106,890.00. Following the sale, the chief executive officer now directly owns 320,424 shares in the company, valued at $34,250,121.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Brian Mueller sold 7,001 shares of the firm's stock in a transaction on Friday, December 2nd. The shares were sold at an average price of $104.50, for a total value of $731,604.50. Following the completion of the sale, the chief financial officer now owns 27,746 shares in the company, valued at $2,899,457. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,880 shares of company stock worth $2,542,028. 1.75% of the stock is currently owned by corporate insiders.
在BioMarin製藥公司的其他新聞中,首席執行官Jean Jacques Bienaime在12月13日星期二的一筆交易中出售了1000股該公司的股票。這隻股票的平均售價為106.89美元,總價值為106,890.00美元。出售後,這位首席執行官現在直接擁有該公司320,424股,價值34,250,121.36美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過這個環節。在BioMarin製藥公司的其他新聞中,首席執行官Jean Jacques Bienaime在12月13日星期二的一筆交易中出售了1000股該公司的股票。這隻股票的平均售價為106.89美元,總價值為106,890.00美元。出售後,這位首席執行官現在直接擁有該公司320,424股,價值34,250,121.36美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過這個環節。此外,首席財務官布萊恩·米勒在12月2日星期五的一次交易中出售了7001股公司股票。這些股票的平均價格為104.50美元,總價值為731,604.50美元。出售完成後,首席財務官現在擁有該公司27,746股,價值2,899,457美元。關於這次銷售的披露可以找到這裏。在過去的三個月裏,內部人士出售了25,880股公司股票,價值2,542,028美元。1.75%的股份目前由企業內部人士持有。
Hedge Funds Weigh In On BioMarin Pharmaceutical
對衝基金入股BioMarin製藥公司
BioMarin Pharmaceutical Price Performance
BioMarin藥品價格表現
Shares of BioMarin Pharmaceutical stock opened at $104.34 on Monday. The stock has a market cap of $19.35 billion, a price-to-earnings ratio of 248.43, a price-to-earnings-growth ratio of 2.38 and a beta of 0.37. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.54 and a current ratio of 5.15. The stock has a 50 day moving average price of $94.35 and a 200-day moving average price of $89.68. BioMarin Pharmaceutical has a one year low of $70.73 and a one year high of $109.56.
週一,BioMarin製藥公司的股票開盤報104.34美元。該股市值為193.5億美元,市盈率為248.43,市盈率為2.38,貝塔係數為0.37.該公司的負債權益比率為0.24,速動比率為3.54,流動比率為5.15。該股的50日移動均線價格為94.35美元,200日移動均線價格為89.68美元。BioMarin製藥的一年低點為70.73美元,一年高位為109.56美元。
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last announced its quarterly earnings results on Wednesday, October 26th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.04. The business had revenue of $505.30 million for the quarter, compared to the consensus estimate of $516.03 million. BioMarin Pharmaceutical had a return on equity of 2.50% and a net margin of 4.18%. The business's revenue was up 23.6% compared to the same quarter last year. During the same period last year, the business posted ($0.03) EPS. Equities analysts expect that BioMarin Pharmaceutical will post 0.87 EPS for the current year.
生物醫藥公司(納斯達克代碼:BMRN-GET Rating)最近一次公佈季度收益是在10月26日星期三。這家生物技術公司公佈本季度每股收益(EPS)為0.16美元,超出分析師普遍預期的0.12美元和0.04美元。該業務本季度的收入為5.053億美元,而普遍預期為5.1603億美元。BioMarin製藥公司的股本回報率為2.50%,淨利潤率為4.18%。與去年同期相比,該業務的收入增長了23.6%。去年同期,該業務公佈了每股收益(0.03美元)。股票分析師預計,BioMarin製藥公司本年度每股收益將達到0.87股。
BioMarin Pharmaceutical Company Profile
BioMarin製藥公司簡介
(Get Rating)
(獲取評級)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
BioMarin製藥公司為患有嚴重和危及生命的罕見疾病和醫療條件的人開發和銷售治療方法。它的商業產品包括Vimizim,一種治療粘多糖病IVA型溶酶體儲存障礙的酶替代療法;Naglazyme,一種用於MPS VI患者的N-乙酰半乳糖胺4-硫酸酯酶的重組形式;以及Kuvan,一種專利的6R-BH4的合成口服形式,用於治療一種遺傳性代謝性疾病苯丙酮尿症(PKU)患者。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取StockNews.com關於BioMarin製藥公司(BMRN)的研究報告
- MarketBeat:回顧一週12/19-12/23
- 這些鋼鐵製造商理應在2023年觀察名單上佔有一席之地
- 通脹降温,標普500指數何去何從
- Cintas以經營槓桿擊敗通脹
- 你買下Palantir的決定可能只是個時間問題
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《BioMarin藥學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioMarin製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。